ValiRx Plc
("ValiRx" or the "Company")
GENERAL MEETING - Adjournment
London, UK . 25 March 2020: ValiRx Plc (AIM: VAL), a clinical stage biotechnology company, provides an update on its Notice of General Meeting ("GM"), which was due to be held today at 11:00.
Due to the current COVID-19 situation, the meeting has been adjourned until further notice.
A further announcement will be made in due course.
For more information, please contact:
|
ValiRx plc |
Tel: +44 (0) 20 7073 2628 |
|
Dr Satu Vainikka, Chief Executive |
Tel: +44 (0) 20 7073 2628 |
|
Tarquin Edwards, Head of Communications. |
Tel: +44 (0) 7879 458 364 |
|
Cairn Financial Advisers LLP - Nominated Adviser |
|
|
Liam Murray / Jo Turner |
Tel: +44 (0) 20 7213 0880 |
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.